Center for Outcomes Research, Real World Evidence and Epidemiology (CORE) Intern jobs in United States
cer-icon
Apply on Employer Site
company-logo

Genmab · 2 weeks ago

Center for Outcomes Research, Real World Evidence and Epidemiology (CORE) Intern

Genmab is an international biotechnology company dedicated to improving the lives of patients through innovative antibody therapeutics. The Center for Outcomes Research, Real World Evidence and Epidemiology (CORE) Intern will work on strategy and projects related to an oncology product approaching launch, gaining exposure to HEOR, RWE, and Medical Affairs teams.

BiotechnologyHealth CareManufacturingMedical
check
Culture & Values
badNo H1Bnote

Responsibilities

Conduct literature search/review re: unmet needs, treatment guidelines, impact of treatment on clinical, economic, patient reported outcomes
Lead HEOR research projects providing input on study design, data analysis and results
Develop/Present (power point slides) on research-related topics to an extended or cross-functional team
Assist in preparations for medical planning and launch planning as appropriate
Assist in preparations for early scientific advice as appropriate

Qualification

SAS/R ProgrammingHEOR researchOncology experienceAI tools for HEORAnalytical skillsOrganizedTime managementVerbal communicationWritten communication

Required

PhD student who has completed course work towards a PhD degree in Epidemiology, Economics, Public Health, Pharmaceutical Policy or a closely related area
Strong analytical skills with the ability to translate key insights into strategy / tactics
Organized and detail-oriented
Excellent time management, verbal & written communication skills
Proficiency in SAS/R Programming and experience in working with claims and electronic health record datasets

Preferred

Experience in oncology therapeutic area
Experience using AI tools for HEOR analyses

Company

Genmab

twittertwittertwitter
company-logo
Genmab is a biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer.

Funding

Current Stage
Public Company
Total Funding
$11.7B
Key Investors
Morgan Stanley Senior FundingGlaxoSmithKlineIndex Ventures
2025-11-18Post Ipo Debt· $6B
2025-09-29Post Ipo Debt· $5.5B
2010-07-01Post Ipo Equity· $134M

Leadership Team

leader-logo
Anthony Pagano
Chief Financial Officer
linkedin
leader-logo
Anthony Mancini
EVP & Chief Operating Officer
linkedin
Company data provided by crunchbase